Human evidence record · Zenagamtide

Subcutaneous amycretin/zenagamtide Phase 1b/2a obesity study

Estimated mean body-weight change included -24.3% at 60 mg vs -1.1% placebo at week 36; lower-dose groups also showed substantial loss.

Quick read

Human evidence record

What this study tells us

Participants were assigned to groups by chance, which helps reduce selection bias. The exact comparator, blinding, population and endpoint still matter when judging the result.

Who was studied?

Adults with overweight or obesity

How many?

n=125

What happened?

Estimated mean body-weight change included -24.3% at 60 mg vs -1.1% placebo at week 36; lower-dose groups also showed substantial loss.

What stops us overclaiming?

Small early-phase parts, different durations/doses, high attrition; not directly comparable with mature Phase 3 obesity trials.

Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →

Key result

Estimated mean body-weight change included -24.3% at 60 mg vs -1.1% placebo at week 36; lower-dose groups also showed substantial loss.

Study details

Study designRandomized controlled early-phase study

PhasePhase 1b/2a

PopulationAdults with overweight or obesity

Sample size125

RouteSubcutaneous

Regimen / exposureMultiple once-weekly dose groups including 1.25, 5, 20 and 60 mg

Duration20–36 weeks depending on study part

ComparatorPlacebo

Primary endpoint / questionSafety/PK and relative body-weight change

Safety resultGI treatment-emergent AEs common; many withdrawals, including substantial discontinuation for reasons unrelated to AEs.

Key limitationsSmall early-phase parts, different durations/doses, high attrition; not directly comparable with mature Phase 3 obesity trials.

Registry / identifierNCT06064006

Open Zenagamtide page →Open primary source →